EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

ACCRELIST LTD (QZG) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of ACCRELIST LTD S$0.02, price S$0.16, upside -87.7%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · SG

AL Thin data Sep 27, 2026

ACCRELIST LTD

QZG · SG

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value 0.0200 SGD · Strongly overvalued (−87.7%)
!Quality 51/100
!Weak Growth (revenue 5y −36.5 %/yr)
!Loss-making · -1.7% net margin (TTM)
✓Low debt · generates free cash flow
!Trails peers (4/11)
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain
Watch ACCRELIST LTD for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.2050 SGD 0.0290 SGD Fair Value 0.0200 SGD Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range 0.0290 SGD – 0.2050 SGD · fair‑value band 0.0200 SGD – 0.0300 SGD · the 0.1630 SGD price screens above the 0.0200 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow ACCRELIST in your weekly email

Every Wednesday you see whether ACCRELIST is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Accrelist Ltd., an investment holding company, engages in the medical aesthetics business in Singapore, Malaysia, and Indonesia. It operates through three segments: Mechanical Business Unit (MBU), Aesthetic Medical Services (AMS), and Others segment.

Show more

Accrelist Ltd., an investment holding company, engages in the medical aesthetics business in Singapore, Malaysia, and Indonesia. It operates through three segments: Mechanical Business Unit (MBU), Aesthetic Medical Services (AMS), and Others segment. The MBU segment offers mould design and fabrication services for consumer electronics, household appliances, automotive, and computer peripherals, as well as precision plastic injection moulding services for customers' finished products. Its AMS segment offers aesthetic services and solutions, including cosmetic dermatology and skin laser services. The company is also involved in the operation of aesthetic medical clinics; retail sale of pharmaceutical and medical goods; and development and distribution of original design manufacturer (ODM) clinical skincare products and other non-ODM products. The company was formerly known as WE Holdings Ltd. and changed its name to Accrelist Ltd. in November 2016. Accrelist Ltd. was founded in 1986 and is headquartered in Singapore.

Stock analysis

ACCRELIST LTD (QZG) currently trades at 0.1630 SGD, while our model-based Fair Value estimate is 0.0200 SGD, 87.7% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of 0.0200 SGD per share, and 0 of the 8 models we run sit above the 0.1630 SGD price.

Bear case: the DCF Models group reads lowest at 0.0200 SGD, and 8 of the 8 models stay below the price. Evidence for this calculation is low.

Scenario range: 0.0200 SGD (bear) to 0.0300 SGD (bull), the price of 0.1630 SGD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

ACCRELIST LTD reported revenue of 15.6M SGD in FY2026 versus 241M SGD in FY2022, a compound −49.5%/yr. Reported net income was −264K SGD in FY2026.

Key figures

Market cap 20.9M SGD (≈ $16.3M) · P/S ratio 1.33 · Net margin −1.7% · Return on equity −10.4% · Return on assets (EBIT) −13.6% · Operating margin −21.5% · Revenue (TTM) 15.6M SGD · Revenue growth (YoY) +27.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 20% below its 52-week high and 426% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −88%, QZG screens richer than that median.

Fair Value models

Bear 0.0200 SGD Fair Value 0.0200 SGD Bull 0.0300 SGD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 0.0200 SGD 0.0200 SGD 0.0300 SGD 82
Growth DCF 0.0200 SGD 0.0200 SGD 0.0300 SGD 80
Owner Earnings 0.0600 SGD 0.0900 SGD 0.1300 SGD 76
All 8 models by family
DCF Models
FCF DCF 0.0200 SGD 0.0200 SGD 0.0300 SGD 82
Owner Earnings 0.0600 SGD 0.0900 SGD 0.1300 SGD 76
5Y Revenue Exit 0.0200 SGD 0.0200 SGD 0.0200 SGD 74
10Y Revenue Exit 0.0200 SGD 0.0200 SGD 0.0200 SGD 68
Multiples
EV/Revenue 0.0100 SGD 0.0200 SGD 0.0200 SGD 54
Asset-Based
NCAV (Graham) 0.0100 SGD 0.0200 SGD 0.0300 SGD 52
Growth DCF
Growth DCF 0.0200 SGD 0.0200 SGD 0.0300 SGD 80
Rev-Margin DCF 0.0200 SGD 0.0200 SGD 0.0200 SGD 74

Open the full fair value analysis →

Notify me when QZG reaches fair value

Put QZG on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 51/100

Of which business quality 50 · Market factors (momentum, volatility) 82

Profitability 27
Margins and returns on capital today
Quality Growth 71
Are margins and returns improving?
Cashflow 23
Earnings quality: real cash, not paper profit
Fin. Strength 46
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 49
Calm price path (market factor)
Momentum 100
Price trend over the last 3–12 months (market factor)
52W Momentum 88
Distance to the 52-week high (market factor)
Net Issuance 70
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 24/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+11.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.5%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−28.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−0.6% (2021) → −17.0% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+46.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about +43.7% a year for the price.

QZG screens overvalued: fair value 88% below the price. Compare with HCA Healthcare, Inc →

Compare ACCRELIST LTD with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 243 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 51 · Below median
Fair Value upside −87.7% · Bottom 25%
Profitability
Return on assets −7.6% · Bottom 25%
Net margin (TTM) −1.7% · Bottom 25%
Operating margin (TTM) −21.5% · Bottom 25%
Growth and dividend
Revenue growth 27.8% · Top 25%
Balance sheet
Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 1.80× · Cheaper than median
P/S (TTM) 1.04× · Cheaper than median
P/FCF 53.1× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 33
FUTURE (revenue growth)100 · sector 29
PAST (return on equity)0 · sector 32
HEALTH (low debt)100 · sector 89
DIVIDEND (yield)0 · sector 38

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $431.63 $597.97 +39%
Fresenius SE FRE €46.15 €34.49 −25%
Dr. Sulaiman Al Habib Medical Services Group 4013 225.00 SAR 109.45 SAR −51%
Tenet Healthcare Corporation THC $257.93 $274.35 +6%
IHH Healthcare Berhad, an investment holding company, 5225 8.03 MYR 4.87 MYR −39%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,889 ₹2,908 −67%
Encompass Health Corporation EHC $123.47 $94.47 −23%
Fresenius Medical Care AG FMS $22.27 $45.84 +106%
DaVita Inc DVA $178.07 $215.81 +21%
Aier Eye Hospital Group 300015 ¥7.91 ¥10.86 +37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ACCRELIST LTD · Fair Value
0.0200 SGD −88%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "ACCRELIST LTD Fair Value". https://www.fairvalue-calculator.com/stock/QZG

Frequently asked questions

Is ACCRELIST LTD (QZG) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of 0.0200 SGD versus a price of 0.1630 SGD, about −88% upside (overvalued).
What is the fair value of QZG?
Our model-based fair value for ACCRELIST LTD is 0.0200 SGD (as of Sep 27, 2026), built from audited fundamentals. The current price: 0.1630 SGD.
What is the quality score of QZG?
ACCRELIST LTD has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ACCRELIST LTD (QZG)?
Our model-based price target is the fair value of 0.0200 SGD (as of Sep 27, 2026) from 8 valuation models. Cautious scenario 0.0200 SGD, optimistic scenario 0.0300 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the ACCRELIST LTD stock forecast for 2026?
Our models put fair value at 0.0200 SGD, about −88% upside versus a price of 0.1630 SGD (overvalued). Cautious scenario 0.0200 SGD, optimistic scenario 0.0300 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of ACCRELIST LTD (QZG)?
ACCRELIST LTD reported trailing-twelve-month revenue of about 15.6M SGD (latest available figure, as of Sep 27, 2026).
What growth is priced into ACCRELIST LTD (QZG)?
For today's price to be fair in a discounted-cash-flow model, ACCRELIST LTD would have to grow free cash flow by +46.6 % per year for five years (discount rate 8.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -36.5 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of QZG use?
Our models discount ACCRELIST LTD at 8.4 %: a base by market capitalisation (nano), damped by beta 0.53, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ACCRELIST LTD that is +46.6 % per year a year over ten years, using the same discount rate (8.4 %) and the same formula as our fair value.
How much growth has ACCRELIST LTD (QZG) delivered so far?
Over the past 5 years revenue at ACCRELIST LTD grew -36.5 % a year. The price currently implies +46.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ACCRELIST LTD (QZG) growing?
The median revenue growth in the sector is +9.8 % a year. That is the yardstick for the growth priced into ACCRELIST LTD (+46.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ACCRELIST LTD (QZG)?
The free-cash-flow yield on the price is 0.59 %: that much free cash flow ACCRELIST LTD produces per unit of market value. When it exceeds the discount rate of our models (8.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ACCRELIST LTD (QZG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ACCRELIST LTD it is 0.0200 SGD per share (as of Sep 27, 2026), against a price of 0.1630 SGD. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is ACCRELIST LTD stock overvalued or undervalued in 2026?
As of Sep 27, 2026, QZG trades above its calculated fair value: price 0.1630 SGD, fair value 0.0200 SGD, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of QZG?
No. The price is what the market pays today (0.1630 SGD); the fair value is what the company's own numbers justify (0.0200 SGD). For ACCRELIST LTD the two are 0.1430 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is ACCRELIST LTD worth?
The market values ACCRELIST LTD at about 20.9M SGD (market capitalisation, as of Sep 27, 2026). Per share that is 0.1630 SGD; our models calculate a fair value of 0.0200 SGD per share.
What do the bullish and bearish scenarios say about QZG?
Our models span a range for ACCRELIST LTD: cautious scenario 0.0200 SGD, base 0.0200 SGD, optimistic 0.0300 SGD per share (as of Sep 27, 2026, price 0.1630 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ACCRELIST LTD (QZG)?
Balance-sheet figures for ACCRELIST LTD (as of Sep 27, 2026): return on equity −10.4%, debt of 0.01 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is QZG from its 52-week high?
ACCRELIST LTD trades at 0.1630 SGD, about 20% below its 52-week high of 0.2050 SGD and 426% above the low of 0.0310 SGD (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0200 SGD is for.
Which stocks are comparable to ACCRELIST LTD?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ACCRELIST LTD stock attractive at the current price?
The data as of Sep 27, 2026: price 0.1630 SGD, calculated fair value 0.0200 SGD (−88%), Quality Score 51/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of QZG calculated?
We run ACCRELIST LTD through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.0200 SGD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. ACCRELIST LTD itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ACCRELIST LTD (QZG)?
The closing price on Oct 2, 2026 was 0.1630 SGD. Our model-based fair value is 0.0200 SGD, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ACCRELIST LTD right now?
The price sits above even our optimistic bull case (0.0300 SGD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of ACCRELIST LTD

How large is the market capitalisation of ACCRELIST LTD (QZG)?
The market capitalisation of ACCRELIST LTD is 20.9M SGD (≈ $16.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ACCRELIST LTD (QZG)?
The price-to-sales ratio of ACCRELIST LTD is 1.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of ACCRELIST LTD (QZG)?
The net margin of ACCRELIST LTD is −1.7% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ACCRELIST LTD (QZG)?
The return on equity (ROE) of ACCRELIST LTD is −10.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ACCRELIST LTD (QZG)?
On an EBIT basis the return on assets of ACCRELIST LTD is −13.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ACCRELIST LTD (QZG)?
The operating margin of ACCRELIST LTD is −21.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ACCRELIST LTD (QZG)?
Revenue at ACCRELIST LTD is growing +27.8% versus a year earlier (3y avg −24.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ACCRELIST LTD (QZG)?
Earnings per share at ACCRELIST LTD are growing +637% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does ACCRELIST LTD (QZG) carry?
The net debt of ACCRELIST LTD is 3.6M SGD (fiscal year 2022, ≈ 11.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch ACCRELIST LTD in the live analysis

One click puts ACCRELIST LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.